RT Journal Article
SR Electronic
T1 IgA dominates the early neutralizing antibody response to SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.10.20126532
DO 10.1101/2020.06.10.20126532
A1 Sterlin, Delphine
A1 Mathian, Alexis
A1 Miyara, Makoto
A1 Mohr, Audrey
A1 Anna, François
A1 Claër, Laetitia
A1 Quentric, Paul
A1 Fadlallah, Jehane
A1 Ghillani, Pascale
A1 Gunn, Cary
A1 Hockett, Rick
A1 Mudumba, Sasi
A1 Guihot, Amélie
A1 Luyt, Charles-Edouard
A1 Mayaux, Julien
A1 Beurton, Alexandra
A1 Fourati, Salma
A1 Lacorte, Jean-Marc
A1 Yssel, Hans
A1 Parizot, Christophe
A1 Dorgham, Karim
A1 Charneau, Pierre
A1 Amoura, Zahir
A1 Gorochov, Guy
YR 2020
UL http://medrxiv.org/content/early/2020/06/11/2020.06.10.20126532.abstract
AB A major dogma in immunology has it that the IgM antibody response precedes secondary memory responses built on the production of IgG, IgA and, occasionaly, IgE. Here, we measured acute humoral responses to SARS-CoV-2, including the frequency of antibody-secreting cells and the presence of specific, neutralizing, antibodies in serum and broncho-alveolar fluid of 145 patients with COVID-19. Surprisingly, early SARS-CoV-2-specific humoral responses were found to be typically dominated by antibodies of the IgA isotype. Peripheral expansion of IgA-plasmablasts with mucosal-homing potential was detected shortly after the onset of symptoms and peaked during the third week of the disease. While the specific antibody response included IgG, IgM and IgA, the latter contributed to a much larger extent to virus neutralization, as compared to IgG. However, specific IgA serum levels notably decrease after one month of evolution. These results represent a challenging observation given the present uncertainty as to which kind of humoral response would optimally protect against re-infection, and whether vaccine regimens should consider boosting a potent, although, at least in blood, fading IgA response.One sentence Summary While early specific antibody response included IgG, IgM and IgA, the latter contributed to a much larger extent to virus neutralization.Competing Interest StatementM.M. received consulting fees from Genalyte Inc. 3 years ago. Other authors declare that they have no competing interests.Funding StatementD.S. was supported for this work by a Pasteur/APHP interface fellowship. The study was supported by Fondation de France, -Tous unis contre le virus- framework Alliance (Fondation de France, AP-HP, Institut Pasteur) in collaboration with Agence Nationale de la Recherche (ANR Flash COVID19 program), and by the SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University ICOViD programs, PI: G.G.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the local ethical committee of Sorbonne Universite (N2020-CER2020-21).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data related to this study are present in the paper or Supplementary Materials.